FDA Extends Review Period for DCCR: What It Means for the PWS Community

On Tuesday, November 26, 2024, Soleno Therapeutics shared an important development regarding the New Drug Application (NDA) for DCCR (diazoxide choline) extended-release tabletsโ€”a potential treatment for individuals with Prader-Willi syndrome (PWS) aged four and older who experience hyperphagia. The U.S. Food and Drug Administration (FDA) has extended the review period for this NDA, pushing the...

FDA Priority Review of DCCR for PWS: Latest Update and What It Means

On October 8, 2024, Soleno Therapeutics provided a regulatory update onย DCCR (Diazoxide Choline Controlled-Release)ย tablets, which are currently undergoingย priority review by the FDAย as a potential treatment for hyperphagia in individuals with Prader-Willi syndrome (PWS). Although the FDA has moved forward with priority review, it has chosen not to hold anย advisory committee meetingย at this time. We have...